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A B S T R A C T   
Bovine mastitis causes changes in the milk and serum proteomes. Here changes in both proteomes caused by naturally occurring subclinical and clinical mastitis have 
been characterised and quantified. Milk and serum samples from healthy dairy cows (n = 10) were compared to those of cows with subclinical (n = 12) and clinical 
mastitis (n = 10) using tandem mass tag (TMT) proteomics. Proteins that significantly increased or decreased in milk (n = 237) or serum (n = 117) were quantified 
and classified by the type of change in subclinical and clinical mastitis. A group of the proteins (n = 38) showed changes in both milk and serum a number of which 
decreased in the serum but increased in milk, suggesting a particular role in host defence for maintaining and restoring homeostasis during the disease. Proteins 
affected by bovine mastitis included proteins in host defence and coagulation pathways. Investigation of the modified proteomes in milk and serum was assessed by 
assays for haptoglobin, serum amyloid A and α1 acid glycoprotein validating the results obtained by quantitative proteomics. Alteration of abundance patterns of milk 
and serum proteins, together with pathway analysis reveal multiple interactions related to proteins affected by mastitis. Data are available via ProteomeXchange with 
identifier PXD022595. 
Significance: Mastitis is the most serious condition to affect dairy cows and leads to reduced animal welfare as well as having a negative economic effect for the dairy 
industry. Proteomics has previously identified changes in abundance of milk proteins during mastitis, but there have been few investigations addressing changes that 
may affect proteins in the blood during the infection. In this study, changes in the abundance of proteins of milk and serum, caused by naturally occurring mastitis 
have been characterised by proteomics using a quantitative approach and both subclinical and clinical cases of mastitis have been investigated. In both milk and 
serum, change in individual proteins was determined and classified into varying types of altering abundance, such as increasing in subclinical mastitis, but showing 
no further increase in clinical mastitis. Of special interest were the proteins that altered in abundance in both milk and serum which either showed similar trends - 
increasing or decreasing in both biological fluids or showed reciprocal change decreasing in serum but increasing in milk. As well as characterising proteins as 
potential markers of mastitis and the severity of the disease, these results provide insight into the pathophysiology of the host response to bovine mastitis.   
1. Introduction 
Bovine mastitis is still a major concern worldwide being a major 
cause of economic losses in the dairy industry due to reduced milk 
production, increased treatment costs, reduced fertility and increased 
culling of affected animals. A wide range of causative pathogens makes 
the treatment of mastitis demanding, with a high risk of the 
development of antimicrobial resistance. Moreover, mastitis poses a 
one-health concern due to a zoonotic potential of particular causative 
microorganisms, such as E. coli, Salmonella spp. or Listeria spp. and the 
potential for food-born infection with a high risk for human health. 
Apart from infectious microorganisms, the causes of mastitis could be, in 
some cases, a traumatic event or even some environmental factors 
(chemical or physical). 
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Mastitis prevalence in dairy cows in Croatia has significantly drop-
ped during the last two decades due to the adoption of European stan-
dards regulating somatic cell count (SCC) and total bacteria count in raw 
milk [1]. Market pressure through the milk conformity standards has 
caused either abandoning milk production by farmers or stronger 
orientation toward commercial production. In commercially oriented 
dairy production, more attention is paid to the management of mastitis. 
Hence the improvement in milk quality is visible through the lower 
prevalence of mastitis. While in some older reports regarding mastitis 
occurrence among dairy cows in Croatia the infection rate was above 
50% of the total udder quarters examined, the most recent report [1] 
showed 13% of quarters were infected. The dominating pathogen was 
Staphylococcus aureus followed by members of genus Streptococcus, 
Trueperella pyogenes, Corynebacterium spp. and Streptococcus uberis, with 
other pathogens isolated only sporadically [1]. 
Diagnosis of clinical mastitis is relatively easy as a range of visible 
clinical signs of udder inflammation along with a disturbance in general 
health are present, but subclinical mastitis diagnosis is challenging due 
to the absence of any visible clinical sign. In daily practice, an increased 
number of SCC in the milk is the only evidence that helps in the diag-
nosis of subclinical mastitis and results in reduced payments to the dairy 
farmer because of reduced milk quality [2]. Somatic cells in milk mostly 
consist of macrophages, neutrophils, lymphocytes and in some degree to 
the presence of mammary epithelial cells. In healthy mammary gland 
secretions, macrophages are the major cell population, but during early 
inflammation neutrophils are the predominant cell type [3]. Upon the 
bacterial invasion of the mammary gland, macrophages respond to 
bacteria and their toxins by releasing cytokines, which recruit leuko-
cytes at the site of infection and trigger the local and systemic acute 
phase response. Understanding the pathogenesis of mastitis, particularly 
the innate and specific immune responses at the systemic level and in the 
mammary gland, including the host-pathogen interaction, is crucial for 
development of reliable biomarkers that might contribute to the diag-
nosis of mastitis in its early stage. 
Over the past decade it has become recognised that during mastitis 
there is a substantial change in the proteins in milk. Decreases are found 
in the more abundant proteins in healthy milk such as the caseins and 
β-lactoglobulin [4], while at the same time an increase occurs in proteins 
of the innate immune system such as haptoglobin (HP) and mammary 
associated serum amyloid A (MSAA3) which are known to be acute 
phase proteins (APP) [5–7]. There has been less focus on the effect of 
mastitis on serum proteins, but it is known that infection of the mam-
mary gland does cause increases in serum APP with elevated HP 
detected in serum of dairy cows with naturally occurring mastitis [8] 
and with raised HP and MSAA3 in experimentally induced mastitis [6]. 
In our previous study, the serum proteome profile was investigated in 
cows with subclinical and clinical mastitis. Several APP, including HP, 
apolipoprotein A-I and inter-alpha-trypsin inhibitor heavy chain 4, were 
differentially expressed in subclinical and clinical mastitis compared to 
the control [9]. There have been further studies on the use of the APP as 
biomarkers of mastitis including studies where their concentrations 
were determined in both milk and serum [10–13]. Correlations between 
the same protein in serum and milk showed variable results with HP 
having a significant correlation but MSAA3 having no correlation be-
tween the levels in these fluids [14]. Inter-alpha-trypsin inhibitor heavy 
chain 4 had a moderate correlation between milk and serum concen-
trations which varied according to the severity and pathogen respon-
sible for the mastitis [13]. 
As well as a growing interest in the acute phase proteins in milk, 
recent investigations have used the increasing power of proteomics to 
examine the change in milk during mastitis [15–22]. 
In contrast, there have been few studies in which proteomics has 
been used to examine both serum and milk from dairy cows with this 
condition. In one study, using two-dimensional electrophoresis (2-DE) 
coupled with Matrix-Assisted Laser Desorption/Ionization Time-of- 
Flight Mass Spectrometry (MALDI-TOF MS), the concurrent changes in 
the proteins in serum and milk whey in response to infection of the 
mammary gland were depicted [23]. Healthy and mastitis serum sam-
ples showed relatively similar protein composition with marked differ-
ences in expression levels, while healthy and mastitis milk whey showed 
a very different composition, likely due to extravasation of blood pro-
teins to the mammary gland. 
A study by Kim et al. [24] characterised immune protein responses to 
mastitis caused by different strains of S. aureus by monitoring serum and 
milk cytokine kinetics and the milk proteome profile. Results demon-
strated differential expression of the cytokines predominately in serum, 
while milk proteomics showed 29 protein spots, which were differen-
tially expressed during the acute or chronic phases of infection. Of these 
component-3 of the proteose peptone (CPP3) was identified as differ-
entially expressed over time and also between the S. aureus challenge 
groups. In another study, a proteomic approach was used to characterise 
the changes in bovine plasma and milk during naturally occurring E. coli 
mastitis. The plasma protein content was not significantly different 
among cows with mild mastitis, severe mastitis, and healthy cows. Ca-
seins levels were decreased, whereas the levels of anti-microbial and 
APP were increased in milk with cows suffering from severe mastitis 
demonstrating the greatest change compared with control cows [25]. 
From these investigations it is clear that using a proteomic approach 
to assess simultaneous change in serum and milk protein in response to 
mastitis might be advantageous. To overcome the shortcomings of the 
gel-based methods used in these previous studies and to increase the 
dynamic range and quantitative accuracy, gel-free and more sensitive 
high-throughput quantitative proteomics methods have been applied in 
this investigation. Thus, the objective of this study was to use a quan-
titative tandem mass tag (TMT) approach to determine the alteration of 
serum and milk proteomes that occur in natural cases of clinical and 
subclinical mastitis, while also comparing the proteomes to those of 
serum and milk from healthy animals. Acute phase protein concentra-
tions were also determined in the serum and milk from the same groups 
to both validate the proteomic results and for comparative analysis of 
the innate immune response in both biofluids. 
2. Material and methods 
2.1. Samples: milk and serum and background on dairy cows 
The study included milk and serum samples taken from thirty-two 
Simmental dairy cows kept on private farms located in the Zagreb 
County, Croatia. All cows were checked by physical examination. So-
matic cell count and California mastitis test (CMT) were performed on 
the milk samples to differentiate samples from quarters with subclinical 
mastitis from healthy milk samples. A threshold of 400,000 cells/ml in 
the SCC was used to select samples for inclusion in the subclinical 
mastitis group. According to the results, cows were assigned into three 
groups: Group H (healthy control, n = 10) consisted of healthy cows 
with SCC below 400,000 cells/ml on the monthly check-up and a 
negative California mastitis test (CMT) on the day of sampling and 
without any clinical sign of mastitis. Group SC (subclinical mastitis, n =
12) comprised cows without clinical signs of mastitis but with SCC above 
400,000 cells/ml on the basis of the monthly check and a positive CMT 
at the time of sampling. Group C (clinical mastitis, n = 10) consisted of 
cows with clinical signs of mastitis which include changes in milk 
appearance (flakes and clots in milk), different stages of udder inflam-
mation (hyperaemia, oedema, pain, udder enlargement and elevated 
udder temperature) and disturbance of general health (depression, 
relaxed cold ears, dehydration, elevated body temperature, increased 
heart and respiratory rate, decreased ruminal contraction and decreased 
appetite). 
Blood samples were taken from v. coccygea and centrifuged at 3000g 
for 15 min after clotting for two hours at room temperature. Serum 
samples were stored at − 80 ◦C until analysis. 
Milk samples were taken aseptically before the morning milking. 
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First few streams were discarded. Teat ends were disinfected with cotton 
swabs soaked with 70% ethanol. Samples were taken into sterile tubes 
and transported to laboratory on ice within a few hours. Milk samples 
were centrifuged at 13000 ×g for 30 min at 4 ◦C to remove cells and fat 
globules. From each sample, the middle clear portion was carefully 
transferred to a clean Eppendorf tube and used for subsequent proteomic 
analysis. 
Bacteriological examination of milk was carried out according to the 
recommendations of the National mastitis council [26]. Aesculin agar 
with addition of 5% ovine blood was used for isolation of pathogens. 
Samples were inoculated on plates and incubated at 37 ◦C for 24 h. 
Grown colonies were identified taking into account morphological (size, 
colour) and physiological properties (Gramm staining, haemolysis, 
catalase and oxidase production). Depending on the initially observed 
properties, colonies were sub cultivated on Baird Parker agar, McConkey 
agar, Triple sugar iron agar (TSI) and Kanamycin aesculin azide agar. 
The ability of staphylococci to produce coagulase was checked using a 
tube coagulase test with rabbit serum. Streptococci were checked using a 
CAMP test. Finally, Gramm positive pathogens were submitted to a 
Micronaut–RPO system for identification based on biochemical re-
actions using 44 different substrates while Micronaut-GNE, based on 24 
substrates was used to identify Gramm negative bacteria. 
2.2. Proteomics: sample preparation of milk and serum; LC-MS/MS 
analysis 
Relative quantification of proteins in milk and serum was performed 
using a shotgun Tandem Mass Tag (TMT)-based proteomic approach 
which has been described previously [27]. In brief, the total protein 
concentration of the samples was determined using the BCA assay 
(Thermo Scientific, Rockford, USA). Internal standards were prepared 
for both milk and serum samples by mixing equal amounts of all milk or 
all serum samples, respectively. An amount of 35 μg of total protein from 
individual samples and internal standards was diluted using 0.1 M 
triethyl ammonium bicarbonate (TEAB, Thermo Scientific, Rockford, 
USA) and subsequently reduced with 20 mM dithiothreitol (DTT) for 60 
min at 55 ◦C (Sigma Aldrich, St. Louis, MO, USA), alkylated with 30 mM 
iodoacetamide (IAA) for 30 min at room temperature in the dark (Sigma 
Aldrich, St. Louis, MO, USA) and acetone-precipitated (6 volumes, 
overnight, − 20 ◦C). Protein digestion was performed using trypsin Gold 
(Promega, Madison, WI, USA) at 1:35 w/w, at 37 ◦C with an overnight 
incubation. Subsequently, peptides were labelled using freshly prepared 
TMT sixplex reagents (Thermo Scientific, Rockford, IL, USA). For each 
sample type (milk and serum), differentially TMT-labelled samples were 
combined with the matching internal standard, aliquoted, dried and 
stored at − 20 ◦C for further DDA LC-MS/MS analysis. 
LC-MS/MS analysis was performed using the Ultimate 3000 
RSLCnano system (Dionex, Germering, Germany) connected to a Q 
Exactive Plus mass spectrometer (MS) (Thermo Fisher Scientific, Bre-
men, Germany) as described elsewhere [30]. After loading onto the trap 
column, peptides were separated on the analytical column (PepMap™ 
RSLC C18, 50 cm × 75 μm) using a linear gradient of 5–45% mobile 
phase B (0.1% formic acid in 80% ACN) over 120 min at the flow rate of 
300 nL/min. Mobile phase A was 0.1% formic acid in water. Ionization 
was achieved using a nanospray Flex ion source (Thermo Fisher Scien-
tific). The MS was operated in positive ion mode using a DDA Top8 
method with parameters set as follows: full scan MS spectra range from 
m/z 350.0 to m/z 1800.0, resolution of 70,000, injection time 120 ms, 
AGC target 1E6, isolation window±2.0 Da and with a dynamic exclusion 
of 30 s. For HCD fragmentation, resolution was set to 17,500 and AGC 
target to 2E5. 
Raw data were analysed using Proteome Discoverer software 
(version 2.3., Thermo Fisher Scientific) with SEQUEST algorithm 
implemented. Database search against Bos taurus NCBInr FASTA files 
(downloaded 04/04/2019, 69,663 entries) was performed according to 
the following parameters: two trypsin missed cleavage sites, precursor 
and fragment mass tolerances of 10 ppm and 0.05 Da, respectively; 
carbamidomethyl (C) fixed peptide modification, oxidation (M) and 
TMT sixplex (K, peptide N-terminus) dynamic modifications. Proteins 
with at least two peptides (including 1 unique) and 5% FDR were 
selected as reliably identified. The internal standard was used to 
compare data between TMT experiments. The mass spectrometry pro-
teomics data for the milk and serum investigations have been deposited 
to the ProteomeXchange Consortium via the PRIDE partner repository 
with the dataset identifier PXD022595 [28]. 
2.3. Statistical and bioinformatic analysis 
All statistics were performed using R v3.2.2 [29]. Sample outliers 
were detected and removed from further analysis per each group, for 
each of the protein using the Dixon’s test from R package outliers v0.14 
[30]. Normality was tested by Shapiro-Wilk test and as the majority of 
analysed proteins did not follow the normal distribution, the difference 
in protein abundance between groups was tested using Kruskal-Wallis 
test. For proteins shown to be significantly differentially abundant 
after P-value correction (false discovery rate, FDR < 0.05), Conover post- 
hoc test was performed for pairwise multiple comparisons using the R 
package PMCMR v4.3 [31]. Fold change between two groups was 
calculated as mean (Case) /mean (Control) and expressed on log2 scale. 
Principal component analysis (PCA) score plot, Volcano plots and vali-
dation plots were designed using R package ggplot2 v3.1.1, the heatmaps 
were designed using R package ggplot2 v3.1.1 and pheatmap 1.0.12 and 
Venn diagrams were designed using web tool InteractiVenn [32–34]. 
Proteins’ GenInfo identifier (GI) accession numbers were converted into 
official gene symbol either by the DAVID conversion tool (https://david. 
ncifcrf.gov/conversion.jsp), UniProtKB ID mapping (https://www.unipr 
ot.org/uploadlists/) or from the Mascot search engine implemented into 
Proteome Discoverer. Pathway enrichment analysis and networks of the 
relationship between desired KEGG pathway and proteins with signifi-
cantly different abundances between groups were designed using 
Cytoscape v3.7.1 [35] plug-ins ClueGO v2.5.7 [36] and CluePedia 
v1.5.7. [37]. Gene ontology (GO) analysis was performed using Protein 
Analysis Through Evolutionary Relationship (PANTHER) classification 
tool (http://www.pantherdb.org/) which uses GO-Slim, a subset of 
terms from the full Gene Ontology database. 
The results from proteomic analysis for HP, SAA1 and ORM1 were 
compared by immunoassay in order to validate obtained proteomic re-
sults. Difference between groups was determined using the Kruskal- 
Wallis test with Conover post-hoc test for pairwise comparisons with 
FDR P-value corrections, separately for each tested protein and valida-
tion method. To compare results of protein levels obtained with these 
validation methods, Spearman’s rank correlation coefficient was 
calculated. 
2.4. Validation of proteomic results 
For validation of results from proteomics the concentrations of HP in 
milk along with SAA and ORM1 in both milk and serum were deter-
mined using Spatial Proximity Analyte Reagent Capture Luminescence 
(SPARCL™) immunoassays [38]. Bovine specific SPARCL assays were 
used for HP, SAA, and ORM1 (Life Diagnostics Inc., West Chester, USA) 
as previously validated [39]. The concentration of the HP in serum was 
determined by a haemoglobin-HP binding assay described by Eckersall 
et al. [40] as modified according to Brady et al. [41]. 
3. Results 
3.1. Health status of cows with subclinical and clinical mastitis and 
healthy cows 
The milk and serum were collected from groups of healthy cows 
(Group H, n = 10), cows with subclinical mastitis (Group SC, n = 12) and 
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clinical mastitis (Group C, n = 10). The health status of the cows 
including bacteriological findings in milk and CMT are presented in 
Table 1 along with their serum concentrations of HP, SAA and ORM1. 
The cows with clinical mastitis demonstrated visible signs of udder 
inflammation in a form of parenchymatous or catarrhal inflammation, 
with changes in milk appearance while cows with subclinical mastitis 
were without any visible sign of inflammation but had increased SCC on 
the monthly check-up and a positive CMT at the time of sampling. 
Causative agents of subclinical and clinical mastitis cases were Strepto-
coccus uberis, Klebsiella spp., Pasteurella spp., Staphylococcus spp., and 
E. coli. 
The serum concentrations of the APP are given in Table 1 demon-
strate the range of concentration found in the different groups during 
mastitis. While there are significant differences between groups as 
shown in the validation section below (Section 3.5), there was a degree 
of overlap between groups, especially for the subclinical group in which 
the ranges from HP (7.4–501 μg/ml) compared to the healthy range 
(2.8–24 μg/ml) and for milk from clinical mastitis (8–842 μg/ml). There 
was a similar spread of results for SAA and ORM1 concentrations in 
serum. 
3.2. Milk proteome in mastitis 
In the milk samples there were a total of 237 unique proteins that 
showed significant differences in abundance between the healthy, 
subclinical and clinical mastitis groups. Within changes in protein 
abundance there were 6 main types of change observed, with majority of 
proteins (213 of the 237 unique proteins) showing one of these 6 main 
types of change in abundance. The types of change are summarized in 
Table 2. The largest number of milk proteins exhibiting a significant 
change (n = 66) were those that showed an increase in clinical mastitis 
compared to the healthy milk (Type 3) but did not show a significant 
increase compared to milk from cows with subclinical mastitis. This was 
followed by proteins (n = 64) that showed an increase in subclinical 
mastitis but no further increase in samples from cows with clinical 
mastitis (Type 1) while there were 23 proteins that increased in sub-
clinical and then exhibited a further increase in clinical mastitis (Type 
2). For proteins that decreased in abundance, the largest number (n =
43) were proteins that showed a decrease in clinical mastitis compared 
to the healthy milk but did not show a significant decrease in cows with 
subclinical mastitis compared to healthy (Type 6). This was followed by 
proteins (n = 13) that showed a decrease in subclinical mastitis and a 
further decrease in samples from cows with clinical mastitis (Type 5) 
whereas there were 4 proteins that decreased in subclinical and but 
exhibited no further decrease in clinical mastitis (Type 4). The 8 milk 
proteins showing the highest fold change in these types of change (Types 
1–6) are listed in Table 3 while the full list of milk proteins in all these 
categories and in further minor types of change are given in Supple-
mentary Table S1. 
The results from proteomic analysis of milk samples between the 
Table 1 
Health status, reproductive status, California mastitis test (CMT) and bacteriology findings in milk and acute phase protein in serum of investigated dairy cows (Group: 
H – healthy control group; Group: SC – subclinical mastitis; Group: C – clinical mastitis). All milk samples in the healthy group had somatic cell count (SCC) of 
<400,000 cells/ml and all milk samples in the subclinical group had SCC of >400,000 cells/ml but no clinical signs of mastitis. All dairy cows in the clinical group 
showed clinical signs of mastitis (hyperaemia, oedema, pain, udder enlargement, elevated udder temperature and clots in the milk).     




















23  negative negative YES 60 136 5.9 1.7 815 
24  negative negative NO  35 3.8 5.7 271 
25  negative negative NO  40 8.6 1.0 352 
26  negative negative YES 102 105 18.3 0.1 274 
27  negative negative YES 60 172 13.8 0.2 208 
28  negative negative YES 50 106 <3 4.3 831 
29  negative negative YES 62 115 5.5 0.2 293 
30  negative negative NO  25 24.3 10 696 
31  negative negative YES 52 106 17.2 NA 288 
32  negative negative YES 101 152 24.2 NA 246 
SC:Sub- 
clinical 
2  +++ negative NO  46 21.4 3.0 234 
3  ++ negative YES 32 96 17.8 3.2 274 
4  + negative YES 118 168 578 168 607 
5  +++ negative NO  72 9.5 4.9 319 
10  +++ negative NO  26 243 49 250 
11  +++ Streptococcus 
uberis 
YES 62 117 7.4 4.3 360 
12  +++ Streptococcus 
uberis 
YES 180 255 13 NA NA 
16  +++ negative YES 245 375 501 129 276 
17  +++ Streptococcus 
spp. 
YES 20 62 10 20 828 
18  ++ negative NO  82 89 23 273 
19  + negative NO  75 7.4 0.3 138 
20  +++ negative YES 210 282 19.1 0.4 177 
C:Clinical 1 Parenchymatous 
mastitis 
++ negative NO  35 305 55 799 
6 Catarrhal mastitis + negative YES 93 150 116 17 351 
7  +++ Pasteurella spp. NO  72 17 42 381 
8 Catarrhal mastitis +++ negative NO  63 8 24 1111 
9 Catarrhal mastitis +++ Staphylococcus 
spp. 
YES 55 105 91 6 438 
13 Catarrhal mastitis ++ Klebsiella spp. NO  150 159 29 444 
14 Catarrhal mastitis ++ negative YES 155 224 143 41 326 
15 Parenchymatous 
mastitis 
++ E.coli NO  55 842 173 175  
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three groups of milk from healthy cows and from those with subclinical 
or clinical mastitis are additionally depicted using PCA score plots 
(Supplementary Fig. S1A) and Volcano plots (Supplementary Fig. S2A). 
The PCA demonstrated that for milk proteins, those that changed in 
subclinical mastitis were separate from the healthy milk proteins but 
still close while the milk proteins from clinical mastitis were substan-
tially apart. The volcano plots for milk proteins show that a greater 
number of milk proteins were significantly increased than decreased in 
abundance especially in the clinical mastitis group when compared to 
the healthy group. 
3.2.1. Differentially abundant proteins in milk during mastitis 
Changes in abundance of individual milk proteins for each main type 
of change as given in Table 3 and shown as heat maps in Fig. 1 and 
Supplementary Fig. S3 show that of proteins that increased in abun-
dance in milk during mastitis the greatest fold change (log2) was in 
haptoglobin (HP) which had a FC of 2.128 in clinical mastitis compared 
to healthy milk, although this was not significantly raised above the 
level found in subclinical mastitis. This pattern of increase (Type 1) was 
shared with serum amyloid A (SAA1), β-defensin (DEFB1), and serpins 
B3 and B1 (SERPINB1, SERPINB3). Proteins showing a significant in-
crease in subclinical mastitis compared to healthy and a further signif-
icant increase in clinical mastitis (Type 2) included α2 macroglobulin 
(A2M), immunoglobulin heavy chain (IGHG), pregnancy zone protein 
(PXP) and cathelicidin 3 (CATH3). There were also proteins that did not 
increase in subclinical mastitis but were increased in clinical mastitis 
(Type 3) including a different variant (19) of A2M, calponin (CNN2) 
cathelicidin1 (CATHL1) and apolipoprotein A-1 and apolipoprotein A-2 
(APOA1, APOA2). 
For milk proteins that decreased in response to mastitis the largest 
group of proteins were those that showed no change in subclinical 
mastitis but demonstrated a significant decrease in abundance in clinical 
mastitis compared to milk from healthy cows (Type 6) with the greatest 
reduction being shown by thrombospondin (THBS1) with a FC of 
− 1.522, along with αS2-casein (CSN1S2), β-lactoglobulin (PAEP) and 
κ-casein (CSN3) among others. Proteins showing significant decreases in 
subclinical mastitis and further decreases in clinical mastitis (Type 5) 
included an ATP-binding transporter (ABCG2), mucin-1 (MUC1) and 
butyrophilin (BTN1A1). Only 4 proteins decreased in subclinical 
mastitis but did not show further change in clinical mastitis (Type 4). 
Pathway analysis of the results for the milk proteome are shown in 
Supplementary Table S3 and Fig. 2 and indicated that complement and 
coagulation cascades, glucagon signalling pathway and glycine, serine 
and threonine metabolism were affected by mastitis. Gene ontology 
analysis (Supplementary Table S4) revealed that for differentially 
abundant milk proteins in molecular function category the largest per-
centage of genes had binding or catalytic activities, for biological pro-
cess cellular, metabolic and regulation were the most common, while 
the highest percentage of genes in cellular component category were 
recognised as cellular anatomical entities. In addition, metabolite 
interconversion enzyme and cytoskeletal protein had the largest percent 
of genes present when looking at the protein class. 
3.3. Serum proteome in mastitis 
In the serum samples there were a total of 117 unique proteins that 
showed significant differences between the healthy, subclinical and 
clinical mastitis groups. Within these proteins there were 6 main types of 
change observed, with majority of proteins (100 of the 117 unique 
proteins) showing one of these 6 main types of change in abundance. 
The types of change are shown in Table 2. The largest number of proteins 
increasing in serum (n = 13) were in proteins that showed an increase in 
subclinical mastitis compared to the healthy serum (Type 1) but did not 
show a further significant increase in serum from cows with clinical 
mastitis. There were 5 proteins that showed no increase in subclinical 
mastitis but did increase in samples from cows with clinical mastitis 
(Type 3) whereas 4 proteins that increased in subclinical did have a 
further increase in clinical mastitis (Type 2). For proteins that decreased 
in abundance, the largest number (n = 48) were proteins that showed a 
decrease in subclinical mastitis compared to the healthy serum but did 
not show a further significant decrease in cows with clinical mastitis 
compared to healthy (Type 4). This was followed by proteins (n = 24) 
that showed a decrease in subclinical mastitis and a further decrease in 
samples from cows with clinical mastitis (Type 5) whereas there were 6 
proteins that decreased in subclinical and exhibited a further decrease in 
clinical mastitis (Type 6). The 8 proteins showing the highest fold 
change in these types of change are listed in Table 4 while the full list of 
serum proteins in all types of change are given in Supplementary 
Table S2. 
The results from proteomic analysis of serum samples between the 
three groups of healthy cows and from those with subclinical or clinical 
mastitis are additionally depicted using PCA score plots (Supplementary 
Fig. S1B), and Volcano plots (Supplementary Fig. S2B). The PCA 
demonstrated that for serum proteins, those that changed in subclinical 
mastitis were separate from the healthy serum proteins but clustered 
closely with serum proteins from clinical mastitis (Supplementary 
Fig. S1B). The volcano plots for serum proteins show that a greater 
number of serum proteins were significantly decreased than increased in 
abundance when comparing the subclinical and clinical mastitis groups 
to the healthy group. 
3.3.1. Differentially abundant proteins in serum during mastitis 
Changes in abundance of individual serum proteins for each type of 
change are given in Table 4 and shown as heat maps in Fig. 3 and 
Supplementary Fig. S4. In contrast to differentially abundant protein in 
milk, more proteins reduced in abundance in serum (n = 78) than 
increased in abundance (n = 22). The majority of these were in the 
group of proteins that were reduced in subclinical mastitis but did not 
show a further fall in abundance (Type 4) in cows with clinical mastitis. 
Among these were immunoglobulin -l (VL1X) with the largest fall in 
abundance of a FC of − 1.709, transthyretin (TTR), phospholipid transfer 
protein (PLTP) and β-casein (CSN2). Among proteins which were 
reduced in serum in subclinical mastitis but had a further significant fall 
in clinical mastitis were carboxypeptidase B2 (CPB2), inter-α-trypsin 
inhibitor heavy chain H1 (ITIH1), antithrombin-III (SERPINC1) and 
peptidoglycan recognition protein (PGYRP2). There were 6 proteins that 
were not reduced in abundance in subclinical mastitis but were signif-
icantly lower in serum from cows with clinical mastitis compared to 
healthy (Type 6) including immunoglobulin heavy chain-δ (IGHD), 
retinol binding protein (RBP4) and gelsolin (GSN). For serum proteins 
that increased in abundance in cows with mastitis, 13 proteins increased 
in subclinical mastitis with no further increase in serum from cows with 
clinical mastitis and included coagulation factor X (F10) and factor IX 
(F9), α1-acid glycoprotein (ORM1) and immunoglobulin heavy chains 
Table 2 
The number of milk and serum proteins showing significant changes between 
Group H (healthy), Group SC (subclinical) and Group C (clinical) mastitis.  
Change 
type 




1 Increase in subclinical; no further increase in 
clinical 
64 13 
2 Increase in subclinical; additional increase in 
clinical 
23 4 
3 No change in subclinical; increase in clinical 66 5 
4 Decrease in subclinical; no further decrease in 
clinical 
4 48 
5 Decrease in subclinical; additional decrease in 
clinical 
13 24 
6 No change in subclinical; decrease in clinical 43 6  
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(IGH, IGHE, IGG). There were 4 proteins which showed an increase in 
subclinical and a further increase in clinical mastitis, being serum am-
yloid A1 and A3 (SAA1, SAA3) and immunoglobulin heavy chains 
(IGHA, IGHD). There were 5 proteins that had no increase in subclinical 
but were increased in clinical mastitis among which were haptoglobin 
(HP) with the highest FC of 2.445, serum amyloid A (SAA3) and lipo-
polysaccharide binding protein (LBP). There were a number of proteins 
(n = 9) which showed an increase in serum from cows with subclinical 
mastitis, but which had a significantly lower abundance in serum from 
cases of clinical mastitis than those with subclinical mastitis. These 
included selenoprotein (SELENOP), CD59 molecule (CD59), comple-
ment C3 (C3) and complement C4 binding protein (C4BPA). 
Pathway analysis of the results for the serum proteome are shown in 
Supplementary Table S3 and Fig. 4 and indicated that complement and 
coagulation cascades and cholesterol metabolism were among pathways 
affected by mastitis leading to change in serum proteins. Gene ontology 
analysis (Supplementary Table S4) revealed that grouping of genes 
identified for differentially abundant serum proteins were similar to 
milk proteins in the relevant categories. Thus, for molecular function the 
largest percentage of genes of serum proteins had binding or catalytic 
activities, cellular, metabolic and regulation were the most common 
biological process, while cellular anatomical entities were the most 
common in cellular component category. Regarding protein class, serum 
proteins were most abundant for protein-binding activity modulator 
class. 
Table 3 
Changes in milk proteins in main categories of change listing up to the 8 proteins most increased or decreased in the category; groups abbreviation: H – control group; 
SC – subclinical mastitis; C – clinical mastitis. For proteins showed to be significantly differentially abundant after P-value correction (FDR < 0.05), Conover post-hoc 
test was performed for pairwise multiple comparisons using the R package PMCMR v4.3 [31]. Fold change between two groups was calculated as for example mean 
(C)/ mean(H) and expressed on log2 scale. NS = not significant  
Accession Number Gene Description FDR log2 fold change 
SC vs H C vs SC C vs H 
Type 1 change: increase in SC and no further increase in C (n = 64) 
2144490 HP Haptoglobin, bovine 0.009 1.484 NS 2.128 
296471870 SAA1 Serum amyloid A protein 0.021 1.236 NS 2.069 
298775 DEFB10 Beta-defensin (peptide BNBD-10) 0.010 1.138 NS 1.525 
27819614 ACTA1 Actin, alpha skeletal muscle 0.013 1.045 NS 1.709 
1387189648 SERPINB3 Serpin B3 0.021 0.941 NS 1.231 
1387222928 ALDOA Fructose-bisphosphate aldolase C 0.018 0.936 NS 1.596 
1387238032 SERPINB1 Leukocyte elastase inhibitor 0.017 0.896 NS 0.989 
296475914 CALM1 Calmodulin 0.013 0.882 NS 1.548  
Type 2 change: increase in SC and further increase in C (n = 23) 
408689599 A2M Alpha-2-macroglobulin variant 18 0.004 0.376 1.332 1.708 
1150079692 IGHG Immunoglobulin gamma heavy chain 0.005 0.371 1.145 1.516 
1387270777 PZP Pregnancy zone protein 0.005 0.181 0.960 1.141 
296477366 ACTR2 Actin-related protein 2 0.016 0.645 0.913 1.559 
1168625 CATHL3 Cathelicidin-3 0.009 0.984 0.900 1.884 
296487402 LOC511240 Hypothetical protein LOC511240 0.005 0.348 0.809 1.157 
73919851 TAGLN2 Transgelin-2 0.013 0.412 0.723 1.135 
1708945 CATHL6 Cathelicidin-6 0.006 1.158 0.683 1.841  
Type 3 change: no change in SC and increase in C (n = 66) 
408689601 A2M Alpha-2-macroglobulin variant 19 0.004 NS 1.628 1.950 
93204556 CNN2 Calponin-2 0.030 NS 1.116 1.618 
296474766 CATHL1 Cathelicidin-1 0.009 NS 1.507 1.554 
296480244 APOA1 Apolipoprotein A-I preproprotein 0.006 NS 1.376 1.545 
114052298 APOA2 Apolipoprotein A-II 0.016 NS 1.123 1.471 
1083056 HMG-2 Nonhistone chromosomal protein HMG-2, bovine 0.019 NS 0.796 1.371 
296485395 PRTN3 Proteinase 3 0.007 NS 0.917 1.346 
226373739 SERPINA3–6 Serpin A3–6 0.004 NS 1.254 1.306  
Type 4 change: decrease in SC and no further decrease in C (n = 4) 
117306582 SCGB1D Secretoglobin, family 1D, member 2 0.015 − 0.233 NS − 0.544 
50401067 MUC15 Mucin-15 0.012 − 0.349 NS − 0.472 
741933771 SIL1 Nucleotide exchange factor SIL1 0.007 − 0.417 NS − 0.807 
2323398 IGL Immunoglobulin light chain variable region 0.005 − 0.483 NS − 0.777  
Type 5 change: decrease in SC and further decrease in C (n = 13) 
1765910 CD36 PAS-4 0.005 − 0.430 − 0.466 − 0.896 
49259423 PAEP Beta-lactoglobulin 0.005 − 0.447 − 0.677 − 1.124 
2136760 N/A Glycoprotein antigen MGP57/53, mammary gland, bovine 0.005 − 0.509 − 0.523 − 1.033 
157835743 MFGE8 Bovine lactadherin C2 domain 0.005 − 0.529 − 0.461 − 0.990 
547484 SLC34A2 Sodium-dependent phosphate transporter 0.004 − 0.545 − 0.646 − 1.191 
1387237809 BTN1A1 Butyrophilin subfamily 1 member A1 0.005 − 0.589 − 0.593 − 1.182 
528942106 MUC1 Mucin-1 0.004 − 0.625 − 0.334 − 0.959 
112496644 ABCG2 ATP-binding cassette transporter subfamily G member 2 0.010 − 0.830 − 0.323 − 1.153  
Type 6 change: no change in SC and decrease in C (n = 43) 
1391916210 CSN2 Beta-casein 0.005 NS − 0.942 − 1.007 
227993 FABP3 Fatty acid-binding protein 0.018 NS − 0.669 − 1.007 
163115 CLU Glycoprotein III 0.005 NS − 1.096 − 1.067 
144953871 SELENOF Selenoprotein F 0.015 NS − 0.896 − 1.080 
40311084 CSN3 Kappa-casein 0.005 NS − 1.020 − 1.108 
939231248 PAEP Beta-lactoglobulin 0.009 NS − 1.484 − 1.304 
1486942190 CSN1S2 Alpha-S2-casein 0.005 NS − 1.179 − 1.453 
860883 THBS1 Thrombospondin 0.005 NS − 0.963 − 1.522  
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3.4. Milk and serum proteomes compared 
There were 38 proteins which were differentially abundant in both 
milk and serum (Table 5) and these proteins fell into four types of 
change, with 11 proteins that were increased in abundance in both milk 
and serum and 8 proteins that had lower abundance in both milk and 
serum from cows with mastitis than in healthy cows. A further 17 pro-
teins had a higher abundance in milk but a lower abundance in serum 
from cows with mastitis while 2 proteins decreased in milk but increased 
in serum from affected cows. 
The changes in abundance in milk and serum, when in the same 
direction were not always consistent in significant change with severity 
of the mastitis. Thus, HP had higher abundance in milk from both sub-
clinical and clinical cases while in serum only in clinical cases of mastitis 
was an increase in abundance observed. In contrast, ORM1 was 
increased in serum from both subclinical and clinical mastitis cases but 
was only increased in abundance in milk from cows with clinical 
mastitis. Other proteins which were increased in both milk and serum 
were SAA1 and SAA3, serum albumin (ALB) and transferrin (TF). Pro-
teins reduced in abundance in milk and serum included glycoprotein III 
(CLU), CSN2, CSN1S1 and α2-glycoprotein1 (AZGP1). Among the pro-
teins which were increased in abundance in milk but decreased in serum 
were α2-macroglobulin (A2M), α1-microglobulin/bikunin precursor 
(AMBP), amine oxidase (AOC3), APOA2, ITIH2, complement factor B 
(CFB), PGLYRP and RBP. 
Pathway analysis incorporating changes in both milk and serum 
identified only one pathway, the complement and coagulation cascades 
(Supplementary Table S3, Supplementary Fig. S5) being affected in 
relation to both biofluids. The interconnection between proteins 
increasing and decreasing in milk and serum is illustrated in the Venn 
diagrams (Supplementary Fig. S6) indicating the patterns of change in 
the milk and serum from the dairy cows in subclinical and clinical 
mastitis. 
3.5. Validation 
The relative abundance, shown by TMT proteomics of HP in milk 
from healthy cows and those with subclinical or clinical mastitis, are 
shown in Supplementary Table S5 and Supplementary Fig. S7 (a and b) 
along with the concentrations of HP determined by immunoassay for 
milk and by the haemoglobin binding assay for serum HP. For all 
methods of analysis there were significant increases in HP in subclinical 
compared to healthy with further reduced P value in comparison of 
clinical to healthy milk. However, while there was not a significant 
difference for abundance of HP between milk from subclinical compared 
to clinical mastitis, as determined by TMT proteomics, with biochemical 
or immuno-assays a significant increase was evident in the clinical 
samples compared to subclinical. Overall samples the HP abundance 
was significantly correlated to the concentration determined by assay in 
milk (r = 0.897, P < 0.001, n = 30) serum (r = 0.553, P = 0.002) as 
shown in Supplementary Fig. S8 (a and b). 
For SAA in milk and serum the median and range of abundances for 
the healthy, subclinical and clinical are shown in Supplementary 
Table S5 and Supplementary Fig. S7 (c and d) with correlations of r =
0.479, P = 0.038 for milk and r = 0.657, P < 0.001 for serum between 
the methods used (Supplementary Fig. S8 c and d). For ORM1 (ORM1) in 
milk and serum the median and range abundances for healthy, sub-
clinical and clinical cases are shown in Supplementary Table S5 and 
Supplementary Fig. S7 (e and f) with correlations of r = 0.68, P < 0.001 
for milk and r = 0.484, P = 0.007 for serum between the methods used 
(Supplementary Fig. S7 e and f). 
4. Discussion 
4.1. Overview of findings 
Microbiological findings in this study were in accordance with the 
Fig. 1. Heatmap of all milk proteins (groups abbreviation: A – control group; B – subclinical mastitis; C – clinical mastitis). The heat map for milk proteins changing 
in each type of change listed in Table 2 (Type 1-Type 6) is shown in Supplementary Fig. S3. Dairy cow identification numbers are given at the base of the heat map 
and refer to the sample numbers given in Table 1. 
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observed clinical feature, that is the type of mastitis. Coliform bacteria 
such as E. coli and Klebsiella are environmental pathogens often associ-
ated with clinical mastitis. Lipopolysaccharide (LPS), a component of 
the cell wall of gram-negative bacteria, is released from the bacteria 
following cell death and during multiplication. LPS is responsible for 
most pathophysiological reactions and clinical feature in E. coli mastitis. 
After elimination of the infection, signs of inflammation, such as 
increased milk SCC, can persist in the infected quarter for several weeks 
[42]. Streptococcus uberis, another environment-associated pathogen, 
was associated mainly with subclinical mastitis in our study. Cows ac-
quire an infection with S. uberis mainly during the dry period and in-
fections are manifested as acute mastitis, usually during the subsequent 
lactation [43]. However, in most cases of subclinical mastitis no path-
ogen was isolated, suggesting that changes in environmental conditions, 
poor management practices, or stressful conditions might have caused 
an increase of somatic cell count and further affected inflammation of 
the mammary gland [44]. 
Considering that the milk and serum samples were collected from 
natural cases of mastitis, cows may be represented at different stages of 
progression of subclinical and clinical mastitis. Furthermore, different 
pathogens (Table 1) were identified as causative agents and as the cows 
were from different farms with differences in environmental conditions 
these factors could be considered as a limitation of the study but only if 
the objective was to determine responses of the mammary gland to a 
particular pathogen. However, as an objective of the study was to 
identify biomarkers that could be used as diagnostic methods for 
detection and monitoring of mastitis on farms, it is important that 
changes in protein abundance should be applicable to a wider range of 
cases than if the study had been restricted to a single bacterial species 
being the causative pathogen. Nevertheless, it would in the future be 
valuable to assess change to the proteomes of milk and serum caused by 
different bacteria to determine if different patterns of biomarker change 
could be related to the pathogen causing the mastitis. 
The proteomic analysis of milk from dairy cows with mastitis has 
been the subject of several reports, going back to the use of two 
dimensional gel electrophoresis through to the present day and the 
introduction of gel-free quantitative proteomics methods 
[20,21,45–49]. While there have been reports of alterations in serum 
proteins during mastitis, there have been few investigations that used 
the proteomic approach in both biofluids [24,25,50]. In this investiga-
tion, milk and serum samples from healthy dairy cows and those with 
either subclinical mastitis or clinical mastitis, have been subjected to 
quantitative proteomics. Changes in specific protein abundances in both 
biofluids have been compared based on the severity of the disease. This 
has led to fascinating insights into the protein changes in milk and 
serum, being stimulated during the differing severities of mastitis. For 
instance, some proteins such as HP and SAA1 were increased in abun-
dance in milk in subclinical mastitis but did not show further elevations 
in milk from cows with clinical mastitis when measured by TMT quan-
titative proteomics. Other proteins such as CATHL3 were increased in 
subclinical and showed a further increase in clinical mastitis. Further-
more, HP increased in both biofluids, B2M decreased in both biofluids, 
A2M increased in milk and decreased in serum and CD59 decreased in 
milk but increased in serum. 
Overall, of 237 proteins with significant differences in abundances 
between the healthy, subclinical and clinical mastitis groups in the milk 
proteome, the majority (153 proteins) showed some type of higher 
abundance in subclinical and clinical groups compared to healthy cows 
(change types 1–3). An opposite trend was found in the serum proteome, 
with most of the proteins (78 of 117) showing lower abundance in the 
subclinical and clinical groups compared to healthy group (change types 
4–6). The increased abundance of proteins in milk could be explained by 
Fig. 2. Interactions of milk proteins with their enriched pathways.  
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a mix of local synthesis in the mammary gland and by extravasation of 
blood proteins to the mammary gland through blood-mammary gland 
barrier. The overall decrease in abundance of a number of serum pro-
teins could be caused by consumption during systematic inflammatory 
response in a negative APP response and/or leakage and transfer of 
proteins to the mammary gland. 
Gene ontology analysis gave similar patterns of changes in genes for 
the proteins of milk and serum for molecular function, biological pro-
cess, and cellular component. This is likely to be due to the primary 
function of milk and serum in secretion of metabolites for growth and 
maintenance along with protection from environmental pathogens. Of 
relevance is that enzymic activity for metabolite interconversion, 
binding activities along with cytoskeletal proteins were among the 
functions of genes identified in both milk and serum, indicating the 
importance of metabolic change and transport functions in both, but 
also that cellular turnover in cytoskeleton is a feature of the response to 
mastitis. 
4.2. Changes in the milk proteome during mastitis 
The pathogenesis of mastitis involves a complex set of interactions 
between an invading pathogen and the immune systems of the host. 
Taking into account the complex nature and the high dynamic range of 
the milk proteome, a quantitative proteomic approach and the associ-
ated bioinformatics analysis, are considered as complementary tools for 
the comprehensive study of the dynamic interactions between the im-
mune system and pathogens. 
It has been shown by several groups that the milk proteome un-
dergoes considerable modification during bovine mastitis. The findings 
here are in general agreement with previous studies with many of the 
protein responses to the infection of the mammary gland having been 
previously described [20,46]. For example HP, SAA1, DEFB10, SER-
PINB3 had been previously observed to increase in milk from cows with 
mastitis [51]. However it was found here that these proteins were 
increased in subclinical mastitis relative to healthy cow milk, but the 
Table 4 
Changes in serum proteins in main categories of change listing up to the 8 proteins most increased or decreased in the category; groups abbreviation: H – control group; 
SC – subclinical mastitis; C – clinical mastitis. For proteins showed to be significantly differentially abundant after P-value correction (FDR < 0.05), Conover post-hoc 
test was performed for pairwise multiple comparisons using the R package PMCMR v4.3 [31]. Fold change between two groups was calculated as for example mean 
(SC)/ mean(H) and expressed on log2 scale. NS = not significant.  
Accession Number Gene Description FDR log2 fold change 
SC vs H C vs SC C vs H 
Type 1 change: increase in SC and no further increase in C (n = 13) 
253723167 F10 Coagulation factor X 0.014 1.684 NS 1.142 
229505 N/A Factor X1 L 0.014 1.684 NS 1.142 
163054 F9 Factor IX (Christmas factor) 0.015 0.886 NS 0.647 
121957959 ORM1 Alpha-1-acid glycoprotein 0.014 0.724 NS 0.780 
1000346 IGH Immunoglobulin heavy chain variable region 0.022 0.621 NS 0.495 
1059270845 N/A Bovine Fab A01 heavy chain 0.027 0.616 NS 0.524 
509264755 IGHE Immunoglobulin epsilon heavy chain variable region 0.017 0.603 NS 0.898 
89611 IGG Ig gamma-2 chain C region, bovine 0.034 0.533 NS 0.620  
Type 2 change: increase in SC and further increase in C (n = 4) 
620597439 SAA3 Serum amyloid A3 0.012 1.012 0.645 1.657 
296471870 SAA1 Serum amyloid A protein 0.011 1.029 0.636 1.665 
509264888 IGHA Immunoglobulin alpha heavy chain variable region 0.014 0.667 0.195 0.861 
509264513 IGHD Immunoglobulin delta heavy chain variable region 0.014 0.667 0.195 0.861  
Type 3 change: no change in SC and increase in C (n = 5) 
2144490 HP Haptoglobin, bovine 0.029 NS 1.853 2.445 
8574568 SAA3 Serum amyloid A protein 0.012 NS 1.280 1.553 
14139702 N/A Unnamed protein product 0.022 NS 0.787 1.534 
108860784 LBP Lipopolysaccharide-binding protein 0.025 NS 0.920 0.755 
1059270816 N/A Fab F08_B11 heavy chain 0.022 NS 0.785 0.749  
Type 4 change: decrease in SC and no further decrease in C (n = 48) 
15866746 FN1 Fibronectin 0.008 − 0.711 NS − 0.723 
1387191381 IL1RAP Interleukin-1 receptor accessory protein 0.025 − 0.725 NS − 0.942 
1387239638 C4A Complement C4-A 0.024 − 0.738 NS − 0.536 
508834 IGHV Anti-respiratory syncytial virus Ig heavy chain V region 0.025 − 0.767 NS − 0.575 
119388700 CSN2 Beta-casein 0.020 − 0.846 NS − 0.426 
1387203538 PLTP Phospholipid transfer protein 0.021 − 0.866 NS − 0.662 
74267870 TTR Transthyretin 0.011 − 0.876 NS − 0.898 
975864 VL1X Immunoglobulin lambda light chain variable region 0.029 − 1.709 NS − 1.542  
Type 5 change: decrease in SC and further decrease in C (n = 24) 
1405680571 F13A1 Coagulation factor XIII A chain 0.017 − 0.383 − 0.232 − 0.616 
114050845 CPB2 Carboxypeptidase B2 0.006 − 0.435 − 0.437 − 0.872 
86438060 C1QB Complement component 1, q subcomponent, B chain 0.019 − 0.465 − 0.336 − 0.801 
296486107 PGLYRP2 Peptidoglycan recognition protein L 0.006 − 0.494 − 0.150 − 0.644 
109940161 SERPINC1 Antithrombin-III 0.006 − 0.521 − 0.107 − 0.628 
296474790 ITIH1 Inter-alpha-trypsin inhibitor heavy chain H1 0.006 − 0.523 − 0.085 − 0.608 
1387235265 ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3 0.006 − 0.560 − 0.083 − 0.642 
1387201758 CPB2 Carboxypeptidase B2 0.029 − 0.806 − 0.417 − 1.224  
Type 6 change: no change in SC and decrease in C (n = 6) 
810213776 C3 Complement component 3 0.025 NS − 0.147 − 0.198 
296475776 C6 Complement component C6 0.037 NS − 0.158 − 0.203 
28189883 LDHB Similar to lactate dehydrogenase B 0.037 NS − 0.143 − 0.253 
296484314 GSN Gelsolin A 0.006 NS − 0.345 − 0.359 
157831280 RBP4 Retinol binding protein 0.019 NS − 0.279 − 0.422 
509264464 IGHD Immunoglobulin delta heavy chain variable region 0.038 NS − 0.306 − 0.456  
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mean concentration was not significantly higher in milk from cows with 
clinical mastitis. Potentially the production of these proteins reaches a 
plateau which is not increased in the clinical disease, either by reaching 
a limit of synthesis or they are removed from the milk at a rate that is 
equivalent to synthesis during the clinical stage of the disease. The mean 
abundance of other milk proteins such as A2M (variant 18), PZP, 
ACTR2, CATHL3, and CNN2 showed a further increase in clinical 
mastitis, compared to their abundance in the subclinical group. These 
proteins showed an association with the disease severity which may be 
of value in monitoring their concentration as an indicator of a subclin-
ical case approaching the clinical level of disease. A third category of 
proteins increasing with mastitis, were those that were not increased by 
subclinical mastitis but were elevated in cases with the clinical disease. 
Among these was A2M (variant 19) and CATHL-1 both of which had 
Fig. 3. Heatmap of all serum proteins (groups abbreviation: A – control group; B – subclinical mastitis; C – clinical mastitis). The heat map for serum proteins 
changing in each type of change listed in Table 2 (Type 1-Type 6) is shown in Supplementary Fig. S4. Dairy cow identification numbers are given at the base of the 
heat map and refer to the sample numbers given in Table 1. 
Fig. 4. Interactions of serum proteins with their enriched pathways.  
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Table 5 
Proteins changing in milk and serum (groups abbreviation: H – control group; SC – subclinical mastitis; C – clinical mastitis). NS = npt significant.  
Accession Number Gene Description Sample log2 fold change 
SC vs H C vs SC C vs H 
Proteins increased in both milk and serum (n = 11) 
74267962 ALB Serum albumin milk NS 1.081 1.066 
1351907 serum 0.442 NS 0.52 
528979082 C4BPA Complement component 4 binding protein, alpha chain milk NS 0.587 0.682 
146231832 serum 0.312 − 0.147 0.164 
2144490 HP Haptoglobin, bovine milk 1.484 NS 2.128 
2144490 serum NS 1.853 2.445 
509264436 IGHD Immunoglobulin delta heavy chain variable region milk NS NS 0.751 
509264513 serum 0.667 0.195 0.861 
1150079692 IGHG Immunoglobulin gamma heavy chain milk 0.371 1.145 1.516 
509264677 serum 0.491 NS 0.693 
15088675 IGLL Immunoglobulin lambda light chain milk 0.252 NS 0.452 
1276609 serum 0.604 − 0.246 0.359 
164450481 KNG1 Kininogen-2 milk NS 0.782 0.968 
164450481 serum 0.367 − 0.168 0.198 
159895416 ORM1 Alpha-1-acid glycoprotein milk NS 0.818 0.624 
121957959 serum 0.724 NS 0.78 
296471870 SAA1 Serum amyloid A1 milk 1.236 NS 2.069 
296471870 serum 1.029 0.636 1.665 
1387253120 SAA3 Serum amyloid A3 milk 1.236 NS 2.069 
620597439 serum 1.012 0.645 1.657 
113911795 TF Transferrin milk NS 0.766 0.855 
602117 serum 0.418 NS 0.349  
Proteins decreased in both milk and serum (n = 8) 
312893 APOE Apolipoprotein E milk NS − 1.328 − 0.99 
1387217499 serum − 0.515 NS − 0.574 
73586954 AZGP1 Alpha-2-glycoprotein 1, zinc-binding milk NS − 0.476 − 0.526 
73586954 serum − 0.308 − 0.262 − 0.57 
550544591 B2M Beta-2-microglobulin milk NS − 0.65 − 0.689 
1387193714 serum − 0.464 0.315 − 0.149 
29,487133 C1S Complement C1s subcomponent milk NS − 0.663 − 0.498 
296487133 serum − 0.372 NS − 0.326 
163115 CLU Glycoprotein III precursor, clusterin milk NS − 1.096 − 1.067 
163115 serum − 0.31 − 0.324 − 0.634 
982928498 CSN1S1 Alpha-S1-casein milk − 0.355 − 1.076 − 1.43 
1387271774 serum − 0.589 NS − 0.481 
1391916210 CSN2 Beta-caesin milk NS − 0.942 − 1.007 
119388700 serum − 0.846 NS − 0.426 
2323398 IGL Immunoglobulin light chain variable region milk − 0.483 NS − 0.777 
1220359011 serum − 0.359 − 0.271 − 0.63 
Proteins increased in milk and decreased in serum (n = 17) 
408689601 A2M Alpha-2-macroglobulin variant 19 milk NS 1.628 1.95 
408689581 serum − 0.251 NS − 0.215 
27806743 AMBP Alpha-1-microglobulin/bikunin precursor (AMBP) protein milk − 0.146 0.737 0.591 
74354219 serum 0.138 − 0.262 − 0.124 
61554,88 AOC3 Copper amine oxidase, liver isozyme milk NS 1.085 1.12 
61680008 serum − 0.281 NS − 0.312 
114052298 APOA2 Apolipoprotein A-II milk NS 1.123 1.471 
114052298 serum − 0.292 − 0.128 − 0.421 
86438511 APOF Apolipoprotein F milk NS 0.962 0.94 
528949675 serum − 0.29 − 0.508 − 0.798 
146345391 CFB Complement factor B milk 0.263 NS 0.505 
146345391 serum − 0.187 NS − 0.26 
81294264 CP Ceruloplasmin milk NS 0.764 0.91 
81294264 serum − 0.308 NS − 0.232 
13358874 HRG Histidine-rich glycoprotein milk NS 0.828 0.836 
13358874 serum − 0.196 − 0.217 − 0.413 
146186952 ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 milk NS 0.827 0.78 
146186952 serum − 0.221 NS − 0.247 
8979739 LDHB Lactate dehydrogenase B milk 0.664 NS 0.809 
28189883 serum NS − 0.143 − 0.253 
201067368 PGLYRP1 Peptidoglycan recognition protein 1 milk 0.631 0.682 1.313 
296486107 serum − 0.494 − 0.15 − 0.644 
415585 RBP4 Retinol binding protein milk NS 0.502 0.556 
157831280 serum NS − 0.279 − 0.422 
520785 SAO Serum amine oxidase milk NS 0.857 0.895 
520785 serum − 0.273 NS − 0.307 
226373739 SERPINA3–6 Serpin A3–6 milk NS 1.254 1.306 
226373739 serum − 0.351 0.238 NS 
157280001 SERPIND1 Heparin cofactor 2 milk NS 0.599 0.685 
528989611 serum − 0.281 − 0.096 − 0.377 
138,222720 SERPINF2 Alpha-2-antiplasmin milk NS 0.737 0.669 
(continued on next page) 
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isoforms in the previous category (increase in subclinical, further in-
crease in clinical) which may mean that immunoassays would not be 
able to differentiate these types of response. CNN2 along with apolipo-
proteins APOA1 and APOA2 were also proteins which were not raised in 
subclinical but were elevated in milk from cows with clinical mastitis. 
The presence of these proteins only in milk from cows with clinical 
mastitis, is presumably linked to their origin, whether it is by release 
from mammary epithelium and the somatic cells, transfer from the blood 
through the mammary blood barrier or breakdown of tissue during the 
inflammatory reaction of the innate immune response to the invading 
bacteria. 
Although proteins that increase in concentration in milk during 
mastitis have had more attention, especially as possible biomarkers of 
the disease, there were significant decreases in abundance of a number 
of milk proteins. It is well established that the major proteins of milk 
decrease in concentration during mastitis [52] and it was observed here 
that variants of β-lactoglobulin (PAEP) were decreased in milk from 
cows with mastitis, where a fall was found in both subclinical and 
clinical or only in the clinical mastitis group. Other proteins that were 
reduced in milk from the cows with mastitis included MUC15 and MUC1 
indicative of a problem with the mammary epithelia which would be a 
normal location for their production and BTN1A1, a component of the 
milk fat globule membrane, showing a further consequence of abnormal 
milk production. 
The changes in the milk proteome found in this investigation are 
consistent with the alterations in milk described previously [46,53,54]. 
Alterations in protein abundance seen when comparing subclinical to 
clinical mastitis have been investigated previously [20,48] and are also 
consistent with the results shown here although there are some differ-
ences in the proteins identified. In comparison to the findings of Maity 
et al. [20] these differences are likely to be related to sample sources, 
sample preparation and the MS used for the investigations. However, the 
main findings of increased changes in milk proteome going from healthy 
milk to subclinical to clinical are similar. The finding that some proteins 
are raised to similar levels in subclinical and clinical groups while other 
proteins show a further increase in clinical while a third group of pro-
teins are only raised in clinical mastitis is a valuable contribution to the 
pathophysiology of the mastitis proteome and may indicate that 
measuring different proteins as potential biomarkers of the disease may 
provide insights into the progression and severity of the disease. 
Pathway enrichment analysis has shown that the mastitis has 
affected diverse pathways of the milk proteome including PPAR sig-
nalling pathway, cholesterol metabolism and complement and coagu-
lation cascades. These pathways are in concordance with pathogenesis 
of mastitis requiring appropriate coordination of multiple signalling 
pathways triggered by innate immune recognition of pathogen mole-
cules, initiating an inflammatory reaction and host defence response. 
The disparate source of the proteins used to determine pathway analysis, 
as the proteins may be secreted from mammary epithelia, somatic cells 
in the milk, deriving from blood neutrophils and from leakage of serum 
proteins through the mammary blood barrier, complicates the inter-
pretation of pathway analysis but it is valuable to know that the host 
response reactions have been activated by the disease. 
The immunoassay by SPARCL of HP in milk showed that there was an 
increase in the amount of HP from the low, virtually undetectable levels 
in milk from healthy cows, increasing in cows with mastitis [55–57]. 
The highest levels were found in the milk from cows with clinical 
mastitis, however this was not a significant difference to that in sub-
clinical mastitis according to the TMT proteomic results but was 
significantly different by immunoassay. Immunoassay using SPARCL for 
M-SAA3, showed increases in the concentration from healthy to sub-
clinical and clinical mastitis and, while proteomics showed significant 
difference between healthy and clinical mastitis groups, immunoassay 
determination also revealed significant difference between subclinical 
and healthy group. Significant difference in abundance for ORM1 was 
detected only by proteomics. These results along with the correlations 
between results of the abundance of the proteins determined by TMT 
proteomics and by SPARCL immunoassay provide validity for the pro-
teomics analysis of milk. 
4.3. Changes in the serum proteome during mastitis 
A lower number of serum proteins showed differential abundance 
compared to proteins in milk, which would be expected with the local 
site of infection being in the mammary gland. Serum proteins of Type 1, 
which increased in the subclinical group, but did not show further in-
creases in the clinical group, were generally host defence proteins, being 
involved in coagulation, antibody and acute phase responses, examples 
being coagulation factor X (F10), Ig heavy chain variable region (IGH) 
and ORM1. Only a few proteins showed an increase in subclinical and 
then a further increase in clinical and were either SAA isoforms (SAA1, 
SAA3) or Ig heavy chain related (IGHA, IGHD). Acute phase proteins 
were prominent among those serum proteins that were not elevated in 
subclinical but were significantly increased in samples from the clinical 
cases, notably haptoglobin (HP), liposaccharide binding protein (LBP) 
and a further form of SAA (SAA3). These changes are consistent with 
observations of serum proteome during mastitis that have previously 
been described [49,58]. 
Serum proteins that decreased in the subclinical group but showed 
no further change in the clinical group included fibronectin (FN1), 
transport proteins such as transthyretin (TTR) and phospholipid transfer 
protein (PLTP) as well as some host defence proteins such as IL-1 rector 
(IL1RAP) and Ig-λ (VL1X). The milk protein, β-casein (CSN2) was found 
in this group, suggesting that in serum from healthy cows it is present in 
serum probably by a low level leakage from the mammary gland. Host 
defence protein were also in the group that decreased in subclinical and 
with a further decrease in clinical mastitis, such as coagulation factor 
XIII (F13A1), complement component 1 (C1QB) and peptidoglycan 
recognition protein L (PGLYRP2). Among these proteins are also mem-
bers of serpin (serine protease inhibitors) family such as antithrombin 
III, inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1) and inter- 
alpha-trypsin inhibitor heavy chain H3 (ITIH3) with functions to pre-
vent excess activation of proteases and limit the potential injurious ac-
tions of protease activation on endothelial and epithelial tissues [59]. 
Their gradual decrease with severity of mastitis and subsequent increase 
of inflammation suggest a possibility of transfer across the mammary 
Table 5 (continued ) 
Accession Number Gene Description Sample log2 fold change 
SC vs H C vs SC C vs H 
1387222723 serum − 0.517 0.097 − 0.42 
4680177 VL1X Immunoglobin light chain VJ region milk 0.573 NS 1.034 
975864 serum − 1.709 NS − 1.542 
Proteins decreased in milk and increased in serum (n = 2) 
79157011 CD59 CD59 molecule, complement regulatory protein milk 0.144 − 0.46 − 0.316 
79157011 serum 0.948 − 0.348 0.6 
34538,98 IGH immunoglobulin heavy chain constant region milk NS − 0.418 − 0.347 
1000346 serum 0.621 NS 0.495  
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blood barrier or other form of consumption in responding to the mastitis 
causing pathogens. 
Proteins of host response, including complement C3 and C6 (C3, C6) 
and Ig Δ heavy chain (IGHD) were found to decrease in clinical mastitis 
in serum but not significantly in subclinical mastitis. Gelsolin, the actin- 
scavenging protein, also showed lower abundance only in clinical 
mastitis group. Actins are released into the systemic circulation after 
disruption of the cell membrane as a result of necrosis and were found in 
milk of subclinical mastitis group in higher abundance compared to 
healthy animals. During the scavenging process, actin–gelsolin com-
plexes are formed and subsequently cleared by the reticuloendothelial 
system, resulting in consumption of gelsolin [60]. In different diseases, 
decline of gelsolin precedes, and therefore might predict, tissue and 
organ injury, as well as being a predictor of complications associated 
with actin scavenging and anti-inflammatory features of gelsolin [61]. 
Pathway analysis from the differentially abundant serum proteins 
identified the most altered pathways due to mastitis, such as comple-
ment and coagulation cascade, PPAR signalling pathway and cholesterol 
metabolism. Inflammation and haemostasis are tightly interrelated 
pathophysiologic processes that may affect each other considerably, as 
evidenced in this study by many of the proteins belonging to coagula-
tion, fibrinolysis and complement pathways. Pathway interaction anal-
ysis of serum proteome has affected similar diverse pathways as in the 
milk proteome indicating that the host immune reaction and defence is 
reflected both locally, in the mammary gland, and systemically. 
The findings on serum proteome changes during mastitis and the 
effect of increasing the severity of the condition from subclinical to 
clinical are valuable findings of this investigation. While it has been 
established that there are changes in the serum proteins during this 
condition, especially in the APP [8,62] the range of proteins and the 
modulation in their abundance patterns is providing further insights into 
the pathophysiology of mastitis. While the increase in the abundance of 
host defence protein in serum APP such as HP, SAA and ORM1, was to be 
expected as there would be a cytokine driven innate immune reaction to 
the presence of pathogen or induced by stress, one of major findings was 
that the abundance of a number of proteins decreased in serum during 
mastitis. This could be due to transfer to the mammary gland where the 
front line of defence against infection is taking place. Whether this 
would be by diffusion through weakened tight junction, which also al-
lows the transfer of neutrophils from blood to the mammary gland, or 
whether there is a facilitated transfer would need to be examined in the 
future. Additionally, increased utilisation without replacement by syn-
thesis during systematic inflammatory response could also contribute to 
decreased abundance of some serum proteins. 
The immunoassay by SPARCL of HP in serum showed that there was 
an increase in the amount of HP in the clinical mastitis group compared 
to subclinical group, however this was not a significant difference ac-
cording to the proteomics. This would be expected with the SPARCL 
assay, being of greater accuracy than the TMT quantitative proteomics 
used here. Immunoassay using SPARCL for M-SAA3, showed increases in 
the concentration from healthy to subclinical to clinical, while the TMT 
proteomics only showed significant difference between clinical and 
subclinical group and between clinical mastitis and healthy group. These 
results along with the correlations between results of the abundance of 
the proteins determined by TMT proteomics and by SPARCL immuno-
assay provide validity for the proteomics analysis of milk. 
4.4. Relation of changes in the milk proteome and serum proteome during 
mastitis 
There have been few previous studies that have simultaneously 
examined change in serum and milk proteins during mastitis. Early in-
vestigations of the changes in the proteomes of these biofluids in mastitis 
have used 2-dimension electrophoresis and have found similar results in 
the changes in the high abundant proteins as found in this investigation 
[58]. The use here of TMT quantitative proteomics enabled a deeper 
view of change in the lower as well high abundant proteins allowing 
valuable insights into the host reactions to mastitis. Among the proteins 
(n = 11), that were increased in abundance in both milk and serum most 
had host defence functions including APP such as HP, SAA, and ORM1, 
along with transferrin (TF), Ig Δ and γ heavy chain (IGHD, IGHG) and 
albumin (ALB). Many of the proteins (n = 8) that were reduced in 
abundance in both milk and serum included Ig light chain (IGL) and β-2 
microglobulin (B2M) can also be related to host responses and their 
reduction in abundance may be related to their being used for functional 
roles in the host defence and not being replaced by synthesis at a high 
enough rate. The milk proteins β-casein (CSN2) and a-s1 casein 
(CSN1S1) were also reduced in abundance in serum as well as in milk, 
which would be explained by the reduction of their synthesis in milk 
during mastitis and a concomitant decrease in the serum as less would be 
transferred from the mammary gland to blood which has been shown 
here to occur in serum from healthy cows. 
Of great interest was the finding that proteins (n = 17) were found 
that had an increased abundance in milk but a reduced abundance in 
serum. Among these were proteins involved in host defence such as α2- 
macroglobulin (A2M), α1-microglobulin/bikunin protein (AMBP), pro-
teins involved in transport such as apolipoproteins AII and F (APOA2, 
APOF) and retinol binding protein (RBP4). An explanation for the 
disparity in abundance change that occurred with the development of 
mastitis is that these proteins are required in the mammary gland in the 
host response to the pathogens causing the mastitis and they are trans-
ferred from the blood, thereby increasing the abundance in the milk but 
reducing their abundance in serum with their systemic synthesis rates 
not being sufficient to maintain normal levels in the blood. Changes in 
the abundance levels of these proteins and modulation of their abun-
dance patterns could act as biomarkers of the host response to predict 
infection of mammary gland. If these proteins have a value in combat-
ting the mastitis causing pathogens, their further investigation could 
open up potential therapies based on their action which could be used 
without resorting to antimicrobials known to develop resistance. 
5. Conclusions 
The infection of the mammary gland that causes bovine mastitis 
leads to significant changes in the proteome, both of milk and of the 
serum of the affected dairy cow. Identification of protein profiles in the 
bovine milk and serum is a comprehensive and valuable strategy for 
discovery of potential biomarkers to be used in diagnostics of mastitis, 
disease monitoring and therapeutic possibilities. Alteration of abun-
dance patterns of milk and serum proteins, together with pathway 
analysis revealing multiple interactions related to the proteins affected 
by mastitis, provide a valuable contribution to understanding of mastitis 
pathophysiology and serve as a valuable tool in the development of new 
diagnostic methods. 
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[27] A. Horvatić, N. Guillemin, H. Kaab, D. McKeegan, E. O’Reilly, M. Bain, J. Kuleš, P. 
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[56] U. Grönlund, C. Hultén, P.D. Eckersall, C. Hogarth, K.P. Waller, Haptoglobin and 
serum amyloid A in milk and serum during acute and chronic experimentally 
induced Staphylococcus aureus mastitis, J. Dairy Res 70 (2003), https://doi.org/ 
10.1017/S0022029903006484. 
[57] F.C. Thomas, M. Waterston, P. Hastie, T. Parkin, H. Haining, P.D. Eckersall, The 
major acute phase proteins of bovine milk in a commercial dairy herd, BMC Vet. 
Res. 11 (2015), https://doi.org/10.1186/s12917-015-0533-3. 
[58] I. Alonso-Fauste, M. Andres, M. Iturralde, F. Lampreave, J. Gallart, M.A. Alava, 
Proteomic characterization by 2-DE in bovine serum and whey from healthy and 
mastitis affected farm animals, J. Proteome 75 (2012) 3015–3030, https://doi.org/ 
10.1016/j.jprot.2011.11.035. 
[59] S.M. Opal, C.T. Esmon, Bench-to-bedside review: functional relationships between 
coagulation and the innate immune response and their respective roles in the 
pathogenesis of sepsis, Crit. Care 7 (2003) 23–38, https://doi.org/10.1186/ 
cc1854. 
[60] U. Meier, O. Gressner, F. Lammert, A.M. Gressner, Gc-globulin: roles in response to 
injury, Clin. Chem. 52 (2006) 1247–1253, https://doi.org/10.1373/ 
clinchem.2005.065680. 
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